GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

Clinical trial NCT07301268 · RECRUITING

Trial details

NCT number: NCT07301268
Sponsor: Mayo Clinic
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Glioblastoma, IDH-Wildtype Progressive Astrocytoma, IDH-Mutant, Grade 4 Progressive Glioblastoma Progressive Gliosarcoma Recurrent Astrocytoma, IDH-Mutant, Grade 4 Recurrent Glioblastoma, IDH-Wildtype Recurrent Gliosarcoma Resectable Astrocytoma Resectable Glioblastoma

Start date: 2026-04-01
Primary completion: 2029-04-30
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.